Roivant Sciences Ltd
NASDAQ:ROIV
Intrinsic Value
Roivant Sciences Ltd. engages in the biopharmaceutical business, which develops drug candidates Vants in subsidiary companies. [ Read More ]
The intrinsic value of one ROIV stock under the Base Case scenario is 1.19 USD. Compared to the current market price of 10.84 USD, Roivant Sciences Ltd is Overvalued by 89%.
Valuation Backtest
Roivant Sciences Ltd
Run backtest to discover the historical profit from buying and selling ROIV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of Roivant Sciences Ltd's business.
What risks and challenges
does Roivant Sciences Ltd face in the near future?
Summarize the latest earnings report
of Roivant Sciences Ltd.
Provide P/E
for Roivant Sciences Ltd and its competitors.
Balance Sheet Decomposition
Roivant Sciences Ltd
Current Assets | 6.8B |
Cash & Short-Term Investments | 6.7B |
Receivables | 44.3m |
Other Current Assets | 91.6m |
Non-Current Assets | 505.9m |
Long-Term Investments | 239.9m |
PP&E | 68.8m |
Intangibles | 150.4m |
Other Non-Current Assets | 46.8m |
Current Liabilities | 244.9m |
Accounts Payable | 35.2m |
Accrued Liabilities | 132.6m |
Other Current Liabilities | 77m |
Non-Current Liabilities | 978m |
Long-Term Debt | 403.3m |
Other Non-Current Liabilities | 574.7m |
Earnings Waterfall
Roivant Sciences Ltd
Revenue
|
123.2m
USD
|
Cost of Revenue
|
-15.3m
USD
|
Gross Profit
|
107.9m
USD
|
Operating Expenses
|
-1.2B
USD
|
Operating Income
|
-1.1B
USD
|
Other Expenses
|
5.5B
USD
|
Net Income
|
4.5B
USD
|
Free Cash Flow Analysis
Roivant Sciences Ltd
What is Free Cash Flow?
ROIV Profitability Score
Profitability Due Diligence
Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
ROIV Solvency Score
Solvency Due Diligence
Roivant Sciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Score
Roivant Sciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ROIV Price Targets Summary
Roivant Sciences Ltd
According to Wall Street analysts, the average 1-year price target for ROIV is 16.15 USD with a low forecast of 12.12 USD and a high forecast of 24.15 USD.
Ownership
ROIV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ROIV Price
Roivant Sciences Ltd
Average Annual Return | -10.87% |
Standard Deviation of Annual Returns | 14.7% |
Max Drawdown | -79% |
Market Capitalization | 8.7B USD |
Shares Outstanding | 805 850 000 |
Percentage of Shares Shorted | 6.44% |
ROIV News
Last Important Events
Roivant Sciences Ltd
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Roivant Sciences Ltd
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Roivant Sciences Ltd. engages in the biopharmaceutical business, which develops drug candidates Vants in subsidiary companies. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The firm builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. Its drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Its development-stage product candidates include Tapinarof, Cerdulatinib, IMVT-1401, ARU-1801, Namilumab, LSVT-1701, Cerdulatinib, DMVT-504, DMVT-503, ARU-2801, AFM32 and CVT-TCR-01. Its Vant family includes Dermavant, Immunovant, Aruvant, Proteovant, Lysovant, Kinevant, Affivant, Cytovant, Arbutus, Sio Gene Therapies, Genevant, Silicon Therapeutics, VantAI, Lokavant, Datavant and Alyvant.
Contact
IPO
Employees
Officers
The intrinsic value of one ROIV stock under the Base Case scenario is 1.19 USD.
Compared to the current market price of 10.84 USD, Roivant Sciences Ltd is Overvalued by 89%.